Aagaard, Niels Kristian
Malago, Massimo
De Gottardi, Andrea
Thomas, Michael
Sauter, Gerd
Engelmann, Cornelius
Aranovich, David
Cohen, Michal
Thévenot, Thierry
Ehmann, Thomas
Capel, Jeroen
Angeli, Paolo
Jalan, Rajiv
Stirnimann, Guido
Funding for this research was provided by:
Sequana Medical NV
Article History
Received: 21 October 2021
Accepted: 4 February 2022
First Online: 8 March 2022
Declarations
:
: The experimental protocols of all clinical studies from which data were analysed were approved by the respective IRBs at the participating sites (for names and further details of IRBs/Ethics Committees, see Additional File InternalRef removed: Tables S1, S2, and S3). Informed consent was obtained from all subjects and/or their legal guardian(s). All experimental protocols involving human data were in accordance to guidelines of national/international/institutional relevance and the Declaration of Helsinki.
: Not applicable.
: All authors have received consulting fees and travel support for alfapump<sup>®</sup> working group meeting attendance. ADG has received speaker fees from and participated in a data safety monitoring board for Sequana Medical NV. RJ has research collaborations with Yaqrit and Takeda and is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Ltd. (a spin out company from University College London), Cyberliver Ltd. and Hepyx Ltd. JC is an employee of and holds shares and stock options of Sequana Medical NV. GSt has received speaker fees from Sequana Medical NV.